Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. [electronic resource]
Producer: 20150820Description: 2445-56 p. digitalISSN:- 1557-3265
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- pharmacology
- Drug Monitoring
- Female
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Staging
- Neoplasms -- drug therapy
- Phosphoinositide-3 Kinase Inhibitors
- Quinoxalines -- pharmacology
- Signal Transduction -- drug effects
- Sulfonamides -- pharmacology
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.